Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

The New England Journal of Medicine
R J GrallaC W Young

Abstract

In a study of the effectiveness of high intravenous doses of metoclopramide as an antiemetic, 41 patients with advanced cancer who were being treated with cisplatin were entered into two double-blind trials. In the first trial patients were randomly assigned to receive either metoclopramide or placebo, and in the second trial they received either metoclopramide or prochlorperazine. Patients given metoclopramide had significantly fewer episodes of emesis than patients given placebo (medians, 1.0 vs. 10.5; P = 0.001) or prochlorperazine (medians, 1.5 vs. 12.0; P = 0.005). Metoclopramide was superior to placebo and to prochlorperazine in reducing the volume of emesis (P = 0.001 and P = 0.022, respectively) and was more effective than placebo in shortening the duration of nausea (P = 0.042) and vomiting (P = 0.028). Side effects from metoclopramide were minor, with mild sedation frequently observed; one patient had a brief extrapyramidal reaction. We conclude that metoclopramide in high intravenous doses has greater antiemetic activity than placebo or prochlorperazine in patients receiving cisplatin chemotherapy.

References

Feb 8, 1979·The New England Journal of Medicine·L H Einhorn, S D Williams
Jul 4, 1975·Brain Research·H L BorisonN E Sirett
Mar 28, 1980·JAMA : the Journal of the American Medical Association·V S Lucas, J Laszlo
Jul 2, 1981·The New England Journal of Medicine·K Schulze-Delrieu

❮ Previous
Next ❯

Citations

Apr 15, 1996·Cancer·L Domínguez-OrtegaE Díaz-Gállego
Mar 1, 1997·Medicinal Research Reviews·L M Gaster, F D King
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·S G AllanR C Leonard
Sep 1, 1995·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·V BarbounisA P Efremidis
Nov 1, 1995·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J P Terrey, P A Casey
Sep 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·A L Billett, S E Sallan
Sep 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·P J Hesketh
Sep 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M G KrisL Hinkley
Sep 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·S M Grunberg
Jul 1, 1993·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M Dicato
Jul 1, 1993·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·R J Gralla, R A Clark
Jul 1, 1993·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·R A Clark, R J Gralla
May 1, 1994·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M Soukop
Jan 1, 1985·European Journal of Clinical Pharmacology·R A JossK W Brunner
Jan 1, 1986·European Journal of Clinical Pharmacology·W B Taylor, D N Bateman
Nov 1, 1993·Investigational New Drugs·M Aapro
Jul 1, 1996·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M Dicato
Mar 1, 1988·Digestive Diseases and Sciences·R D CheyW Y Chey
Jan 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·S M Grunberg
Jan 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·B ChevallierN Claverie
Jan 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·E A PerezD Fitts
Jan 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J HerrstedtM Hansen
Nov 1, 1996·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·J Herrstedt
Oct 1, 1991·Breast Cancer Research and Treatment·E CamporaR Rosso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.